Welcome to our dedicated page for Moringa Acquisition news (Ticker: MACA), a resource for investors and traders seeking the latest updates and insights on Moringa Acquisition stock.
Moringa Acquisition Corp (Nasdaq: MACA) is a publicly-listed special purpose acquisition company (SPAC) registered in the Cayman Islands. Known as a blank check company, Moringa was established with the primary goal of merging, amalgamating, or acquiring one or more businesses. The company particularly focuses on Israel-related technology companies.
Recently, Moringa announced a significant business combination agreement with Silexion Ltd., a clinical-stage, oncology-focused biotechnology company. This merger will result in Silexion becoming publicly listed on the Nasdaq, with a pre-transaction equity value set at $62.5 million. This merger, expected to close in the third quarter of 2024, has been unanimously approved by the boards of both companies and is subject to shareholder and regulatory approvals.
Silexion is pioneering RNA therapeutics and has shown promising results in the treatment of non-resectable pancreatic cancer through its product Loder™, which demonstrated a median overall survival advantage in clinical trials. The company is now advancing its second generation product, SIL-204B, to further enhance therapeutic efficacy.
The merger will see Moringa issuing 6.25 million shares to Silexion’s current equity holders. The combined entity will feature a board of seven members, two of whom will be appointed by Moringa’s sponsor.
This business combination promises to leverage Silexion's innovative treatments and Moringa's strategic approach to deliver value to their shareholders, ensuring a robust presence in the biotechnology sector.
Silexion Therapeutics (NASDAQ: SLXN) is emerging as a disruptive player in precision oncology, developing RNAi therapies for KRAS-driven cancers. Their proprietary LODER™ platform has shown promising results in Phase 2 trials for locally advanced pancreatic cancer, demonstrating a 9.3-month improvement in overall survival when combined with standard chemotherapy.
Silexion's second-generation product, SIL-204, targets a broader range of KRAS mutations and is set to enter Phase 2/3 trials in 2025-2026. The company's innovative approach addresses key challenges in pancreatic cancer treatment, including late detection, aggressive tumor growth, and drug resistance.
With the global precision medicine market projected to reach $470.53 billion by 2034, Silexion's focus on KRAS-driven cancers positions it as a potential acquisition target in a landscape of increasing M&A activity in the oncology space.
Moringa Acquisition Corp (NASDAQ: MACA) announced the adjournment of its Extraordinary Meeting, initially scheduled for February 7, 2023, to February 9, 2023. This meeting aims to vote on extending the deadline for completing a business combination from February 19, 2023, to August 19, 2023. Shareholders are advised to participate and review the Definitive Proxy Statement filed with the SEC. The company previously entered into a business combination agreement with Holisto Ltd., a tech-powered travel agency. The record date for shareholders to vote remains January 3, 2023.
On June 13, 2022, Holisto Ltd and Moringa Acquisition Corp (Nasdaq: MACA) announced a merger agreement, enabling Holisto to become publicly listed. The combination values Holisto at approximately $405 million and provides non-redeeming Moringa shareholders with a bonus of up to 1,725,000 shares. Holisto, leveraging AI technology, aims to disrupt the $194 billion online hotel booking market with personalized offerings. The transaction is expected to close in Q4 2022, subject to shareholder and Nasdaq approvals.
Moringa Acquisition Corp (NasdaqCM: MACA, MACAU, MACAW) filed its annual report on Form 10-K for the year ended December 31, 2021, with the SEC on March 31, 2022. This report is accessible through their official website and the SEC's site. The company targets mergers and acquisitions, particularly focusing on technology firms related to Israel. The press release also includes a reminder that forward-looking statements are based on management's beliefs and assumptions, and actual results may differ due to various factors.
Moringa Acquisition Corp has announced the pricing of its initial public offering (IPO) at $10.00 per unit, totaling 10,000,000 units. The units will be listed on Nasdaq under the symbol 'MACAU' starting February 17, 2021. Each unit includes one Class A ordinary share and one-half of a redeemable warrant, allowing the purchase of additional shares at $11.50. The Company aims to focus on Israel-related technology firms and has engaged EarlyBirdCapital, Inc. and Moelis & Company as joint book-running managers. A registration statement was approved by the SEC on February 16, 2021.
FAQ
What is the current stock price of Moringa Acquisition (MACA)?
What is the market cap of Moringa Acquisition (MACA)?
What is Moringa Acquisition Corp?
What recent business combination did Moringa announce?
When is the Moringa and Silexion merger expected to close?
What does Silexion specialize in?
What is the pre-transaction equity value of Silexion in the merger?
How many shares will Moringa issue to Silexion's equity holders?
What clinical product has Silexion developed?
Who are the legal advisors for Moringa and Silexion in this transaction?
What will be the composition of the new board of directors post-merger?
Where can I find more information about the proposed business combination?
